Lattice Medical Revolutionizes Breast Reconstruction with Record 43 Million Funding
The French startup Lattice Medical has secured a historic funding round of 43 million euros, setting a new paradigm in the field of medical biotechnology specialized in breast reconstruction. This unprecedented financial milestone will accelerate the development and commercialization of its MATTISSE technology, a completely innovative approach that rethinks traditional reconstructive procedures after mastectomies. 🎯
MATTISSE Technology: Advanced Bioprinting with Smart Materials
The MATTISSE system represents a radical change in regenerative medicine through the integration of 4D bioprinting with next-generation biodegradable biomaterials. Unlike conventional implants that remain in the body, this methodology uses the patient's own adipose tissue to manufacture a personalized scaffold that is progressively reabsorbed while the natural breast tissue regenerates.
MATTISSE Reconstructive Process:- Three-dimensional scanning of the healthy contralateral breast to design a perfectly symmetrical and personalized implant
- Bioprinting of the scaffold with specialized bioink that ensures total biological compatibility
- Filling with autologous fat using advanced lipotransfer techniques minimizing rejection risks
While traditional companies continue to perfect implants that will eventually need to be replaced, Lattice Medical bets on a solution where the body literally reconstructs itself.
Clinical Advances and Implementation Strategy
The ongoing clinical trials demonstrate exceptionally positive results with substantial improvements in patients' quality of life, including significant reduction in postoperative pain, accelerated recovery, and notably superior aesthetic outcomes. The funding obtained will allow expansion of the studies to multiple European hospital centers and expedite obtaining CE certification.
Upcoming Developments and Expansion:- Expansion of clinical trials to reference medical centers in Europe
- Acceleration of the certification process for European commercialization
- Parallel development of the EVE system for ovarian reconstruction demonstrating technological versatility
Future of Regenerative Breast Reconstruction
Lattice Medical's timeline projection estimates that MATTISSE could be commercially available in Europe within two years, establishing a new standard of excellence in reconstructive surgery. This pioneering technology demonstrates that the most effective solution may lie in enhancing the body's natural regeneration mechanisms rather than trying to replace them. 🌱